AFT expands further
May 11, 2016
AUSTRALIA-BASED AFT
Pharmaceuticals has extended its
existing agreements with privately owned
Swiss headquartered
multinational pharmaceutical
company, Acino Pharma AG, to
out-license the product line of its
patented combination painkiller,
Maxigesic, to a further 11 countries,
bringing the total to 109 markets.
New countries covered by the
agreement are primarily in the
Commonwealth of Independent
State region, namely Ukraine,
Belarus, Armenia, Azerbaijan,
Kazakhstan, Kyrgyzstan, Moldova,
Turkmenistan, Tajikistan, Uzbekistan
and Georgia.
Maxigesic consists of a patented
fixed ratio of ibuprofen for anti inflammation
management and
paracetamol for pain management
in tablet, sachet, oral liquid, fast dissolve
and intravenous forms.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 May 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 16
